在压力过载引起的心力衰竭中发生的全身代谢重塑表明肠肝心轴的调节是由阿迪波内克丁受体激动剂ALY688的调节
Yubin Lei1, Benjie Li2, Tori Gosse1
1Department of Biology, York University, Toronto, ON M3J 1P3, Canada.
Metabolites
|January 27, 2026
概括
白素受体激动剂ALY688通过恢复全身代谢平衡来减轻心力衰竭中的代谢干扰,从而降低排气分数 (HFrEF). 这表明肠-肝-心轴对ALY688至关重要.
科学领域:
- 心血管疾病研究研究
- 代谢学 代谢学 代谢学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在心脏代谢性疾病 (CMD) 的动物模型中,阿迪波涅丁已经证明了心脏保护作用.
- 阿迪波涅克丁受体激动剂ALY688显示出对压力过载诱导的心脏重塑在心力衰竭与减少射出分数 (HFrEF) 的承诺.
- 具体的代谢物及其在心脏缩或心力衰竭中的作用仍然不清楚.
研究的目的:
- 在HFrEF中的五种组织中表征系统代谢变化.
- 确定ALY688如何修改这些途径以调解心脏保护.
- 为了研究ALY688的作用机制中的肠-肝-心轴.
主要方法:
- 使用液体染色学-并联质谱法 (LC-MS/MS) 进行有针对性的代谢分析.
- 对心脏,肝脏,肌肉, epididymal 白脂肪组织 (eWAT) 和来自小鼠的血清进行分析.
- 在Sham,横向大动脉收缩 (TAC) 诱导的HFrEF和ALY688治疗的TAC组之间进行比较.
主要成果:
- TAC诱导了系统代谢平衡的广泛破坏.
- ALY688治疗显著改变了甘油三 (TGs) 和甘油三 (HexCer).
- ALY688调节的肠道衍生代谢物 (TMAO,5-AVA,GDCA),表明一个肠-肝-心轴.
结论:
- ALY688在多种组织中减轻了TAC诱导的代谢失调.
- ALY688的心脏保护作用包括恢复系统代谢平衡.
- 这些发现支持ALY688在HFrEF的潜在治疗作用,通过肠-肝-心脏代谢轴.
相关概念视频
01:17Pathophysiology of Heart Failure
3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
01:27Heart Failure I: Introduction
829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
01:29Heart Failure II: Pathophysiology
855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
01:22Heart Failure Drugs: Diuretics
935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
01:30Heart Failure V: Medical Management
267
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
267
01:22Heart Failure VI: Adjunct Therapies
313
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313